Time course of histological progression in primary sclerosing cholangitis

被引:49
作者
Angulo, P
Larson, DR
Therneau, TM
LaRusso, NF
Batts, KP
Lindor, KD
机构
[1] Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol, Dept Hlth Sci Res, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, Lab Med & Pathol, Rochester, MN USA
关键词
D O I
10.1111/j.1572-0241.1999.01543.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
OBJECTIVE: The aim of this study was to determine the time course over which patients with primary sclerosing cholangitis (PSC) progress through the histological stages of the disease. METHODS: One hundred seven patients with PSC who had at least two liver biopsies were identified. The stage information from two consecutive biopsies formed one observation and a continuous time Markov model was used to describe the rate of progression between biopsies. RESULTS: Three hundred seven liver biopsies were performed in the 107 patients giving a total of 200 observations. At 1 yr, 42% of patients in stage II disease progress, 66% at 2 vr, and 93% at 5 yr; whereas 14% of patients in stage III progress at 1 yr, 25% at 2 yr, and 52% at 5 yr. The frequency of progression of stage I disease could not be determined because of the small number of patients in stage I. Regression of histological stage was observed in 30 of 200 total observations (15%), and in 30 of 85 observations (35%) in which there was a change in stage. CONCLUSIONS: These data regarding histological progression in PSC may be potentially helpful in determining the number of patients and length of time necessary to appreciate a treatment effect in clinical trials. However, the high degree of sampling variability in PSC may restrict the usefulness of serial liver biopsies as a means of evaluating treatment efficacy. (C) 1999 by Am. Cell. of Gastroenterology.
引用
收藏
页码:3310 / 3313
页数:4
相关论文
共 19 条
[11]   PROSPECTIVE TRIAL OF PENICILLAMINE IN PRIMARY SCLEROSING CHOLANGITIS [J].
LARUSSO, NF ;
WIESNER, RH ;
LUDWIG, J ;
MACCARTY, RL ;
BEAVER, SJ ;
ZINSMEISTER, AR .
GASTROENTEROLOGY, 1988, 95 (04) :1036-1042
[12]   RESOLUTION OF RADIOGRAPHIC ABNORMALITIES WITH URSODEOXYCHOLIC ACID THERAPY OF PRIMARY SCLEROSING CHOLANGITIS [J].
LEBOVICS, E ;
SALAMA, M ;
ELHOSSEINY, A ;
ROSENTHAL, WS .
GASTROENTEROLOGY, 1992, 102 (06) :2143-2147
[13]   Ursodiol for primary sclerosing cholangitis [J].
Lindor, KD .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (10) :691-695
[14]   Time course of histological progression in primary biliary cirrhosis [J].
Locke, GR ;
Therneau, TM ;
Ludwig, J ;
Dickson, ER ;
Lindor, KD .
HEPATOLOGY, 1996, 23 (01) :52-56
[15]  
LUDWIG J, 1986, LIVER PATHOLOGY CONT, P193
[16]  
Mitchell S A, 1998, Clin Liver Dis, V2, P353, DOI 10.1016/S1089-3261(05)70012-X
[17]   PATIENTS WITH ASYMPTOMATIC PRIMARY SCLEROSING CHOLANGITIS FREQUENTLY HAVE PROGRESSIVE DISEASE [J].
PORAYKO, MK ;
WIESNER, RH ;
LARUSSO, NF ;
LUDWIG, J ;
MACCARTY, RL ;
STEINER, BL ;
TWOMEY, CK ;
ZINSMEISTER, AR .
GASTROENTEROLOGY, 1990, 98 (06) :1594-1602
[18]   EFFECT OF URSODEOXYCHOLIC ACID ON LIVER AND BILE-DUCT DISEASE IN PRIMARY SCLEROSING CHOLANGITIS - A 3-YEAR PILOT-STUDY WITH A PLACEBO-CONTROLLED STUDY PERIOD [J].
STIEHL, A ;
WALKER, S ;
STIEHL, L ;
RUDOLPH, G ;
HOFMANN, WJ ;
THEILMANN, L .
JOURNAL OF HEPATOLOGY, 1994, 20 (01) :57-64
[19]   PRIMARY SCLEROSING CHOLANGITIS - NATURAL-HISTORY, PROGNOSTIC FACTORS AND SURVIVAL ANALYSIS [J].
WIESNER, RH ;
GRAMBSCH, PM ;
DICKSON, ER ;
LUDWIG, J ;
MACCARTY, RL ;
HUNTER, EB ;
FLEMING, TR ;
FISHER, LD ;
BEAVER, SJ ;
LARUSSO, NF .
HEPATOLOGY, 1989, 10 (04) :430-436